ALNY vs ARGX vs ROIV Stock Comparison

Alnylam Pharmaceuticals, Argenx Se and Roivant Sciences Prices as of Nov 13, 2026 Peers: Industry group
ARGX Argenx Se
$960.04 +17.3% 1M +7.7% 1Y
Market cap
$58.18B
P/E
31.0x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
3 wins
ROIV Roivant Sciences Ltd.
$39.53 +17.6% 1M +92.3% 1Y
Market cap
$27.84B
P/E
–
Revenue (TTM)
$41.08M
Div. yield
–
Biotechnology Healthcare
3 wins

Head to Head

9 decided of 12

Argenx Se leads on 3 of the 12 questions below (Argenx Se 3, Alnylam Pharmaceuticals 3, Roivant Sciences 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALNYARGXROIVLeader
Larger companyMarket capitalisation $21.33B $58.18B $27.84B ARGX
Cheaper on earningsLower P/E, profitable companies only 8.1x 31.0x -80.8x ALNY
Cheaper on forward earningsLower price / next fiscal year consensus EPS 8.6x 32.8x — ALNY
Faster revenue growthRevenue growth, trailing twelve months +60.8% +61.5% +102.1% ROIV
More profitableNet margin, trailing twelve months 52.8% 32.3% -838.2% ALNY
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA -3.1x — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -63.6% +7.7% +92.3% ROIV
Better 5-year returnAnnualised price return, 5 years -0.7%/yr +25.4%/yr +36.3%/yr ROIV
Less volatileAnnualised volatility, 1 year 59.1% 37.7% 46.2% ARGX
Higher overall scoreMean of the five percentile scores vs peers 81/100 92/100 78/100 ARGX

Percentile Scorecard

ALNYARGXROIV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALNYARGXROIV
Valuation 91 #61 of 660 82 #122 of 660 69 #207 of 660
Growth 99 #10 of 619 96 #27 of 619 86 #88 of 619
Profitability 91 #55 of 595 99 #9 of 595 51 #294 of 595
Financial Health 61 #269 of 683 – 93 #47 of 683
Shareholder Returns 66 #156 of 459 – 92 #40 of 459
Overall 81 92 78
  • ALNY ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ARGX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ROIV ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALNYARGXROIVSPY
1 month -26.5%+17.3%+17.6% -2.0%
3 months -27.8%+12.8%+9.2% -2.8%
6 months -42.5%+20.1%+35.0% +2.0%
Year to date -58.5%+14.2%+82.2% +10.6%
1 year -63.6%+7.7%+92.3% +12.2%
3 years -2.9%+96.0%+325.1% +68.1%
3 years, per year -1.0%+25.2%+62.0% +18.9%
5 years -3.4%+210.1%+370.6% +61.4%
5 years, per year -0.7%+25.4%+36.3% +10.1%
10 years +254.6%—— +248.5%
10 years, per year +13.5%—— +13.3%

Risk

MeasureALNYARGXROIVSPY
Volatility, 1Y 59.1%37.7%46.2% 13.6%
Downside volatility, 1Y 74.1%35.2%33.3% 13.9%
Beta vs S&P 500, 1Y 0.500.541.10 1.00
Return / volatility, 1Y -1.080.202.00 0.90
Max drawdown, 5Y -69.1%-38.2%-79.2% -25.4%
From 52-week high -65.1%-9.3%-5.5% -3.2%
52-week high $473.29$1,058.90$41.85 $779.14
52-week low $151.64$663.93$20.10 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALNYARGXROIV
P/E now vs peer median 8.3xmedian 17.0x 31.4xmedian 17.0x -83.0xmedian 17.0x
P/S now vs peer median 4.4xmedian 8.4x 10.2xmedian 8.4x 696.3xmedian 8.4x
EV/EBITDA now vs peer median 18.3xmedian 14.6x —median 14.6x -43.9xmedian 14.6x
P/FCF now vs peer median 27.4xmedian 19.0x —median 19.0x -858.0xmedian 19.0x
P/B now vs peer median 6.1xmedian 2.0x —median 2.0x 6.2xmedian 2.0x
PEG now vs peer median 0.09median 0.43 0.30median 0.43 -2.97median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALNYARGXROIV
Revenue $5.01B $5.82B $41.08M
Gross profit $3.88B $5.24B $36.43M
Operating income $977.59M $1.74B -$557.96M
Net income $2.65B $1.88B -$440.18M
Free cash flow $806.31M – -$33.34M
R&D $1.56B $1.80B $712.09M
EPS (diluted) $19.19 $28.43 $-0.48
Cash & equivalents $1.75B – $1.64B
Total debt $361.53M – –
Shares (diluted) 138.04M 66.03M 722.75M
Enterprise value $8.52B $58.18B $10.97B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALNYARGXROIV
P/E 8.3x 31.4x -83.0x
P/FCF 27.4x – -858.0x
P/Operating cash flow 23.1x – -786.2x
P/S 4.4x 10.2x 696.3x
P/B 6.1x – 6.2x
P/Tangible book 6.1x – 6.2x
EV/EBITDA 18.3x – -43.9x
EV/EBIT 19.3x 34.1x -43.7x
EV/Revenue 3.8x 10.2x 593.9x
EV/FCF 23.4x – -731.8x
EV/Operating cash flow 19.7x – -670.5x
PEG (3Y EPS CAGR) 0.09 0.30 -2.97

Growth

14 metrics
MetricALNYARGXROIV
Revenue growth (1Y) 60.8% 61.5% 102.1%
Revenue CAGR (3Y) 42.7% 80.5% 0.9%
Gross profit growth (1Y) 49.6% 62.2% 85.9%
Gross profit CAGR (3Y) 37.8% 80.0% -1.3%
Operating income growth (1Y) 269.3% 120.6% 51.5%
Operating income CAGR (3Y) 68.2% 85.1% 12.5%
Net income growth (1Y) 2,137% 22.5% 15.8%
Net income CAGR (3Y) 93.1% 115.5% 25.4%
EPS growth (1Y) 2,126% 20.9% 13.2%
EPS CAGR (3Y) 90.8% 104.8% 28.0%
Operating cash flow growth (1Y) 351.6% – 95.3%
Operating cash flow CAGR (3Y) 685.4% – 65.0%
Free cash flow growth (1Y) 382.3% – 95.7%
Free cash flow CAGR (3Y) 141.7% – 66.0%

Profitability

14 metrics
MetricALNYARGXROIV
Gross margin 77.4% 90.0% 88.7%
EBITDA margin 20.6% – -1,352%
Operating margin 19.5% 29.9% -1,358%
Pretax margin 15.6% 32.6% -723.4%
Net margin 52.8% 32.3% -838.2%
FCF margin 16.1% – -81.2%
Operating cash flow margin 19.1% – -88.6%
Return on equity 106.4% – -8.1%
Return on assets 38.9% – -7.5%
Return on invested capital – – –
Return on capital employed 20.7% – -11.5%
Asset turnover 0.7x – 0.0x
Cash conversion (OCF / net income) 0.4x – 0.1x
Stock comp / revenue 6.1% – 819.9%

Financial Health

11 metrics
MetricALNYARGXROIV
Debt / assets 4.5% – –
Debt / equity 0.1x – –
Net debt / EBITDA -3.1x – –
Debt / FCF 0.4x – –
Liabilities / assets 54.9% – 7.6%
Equity / assets 45.1% – 92.4%
Interest coverage 3.2x 10,120x –
Current ratio 2.5x – 15.6x
Quick ratio 2.3x – 15.0x
Cash ratio 1.7x – 15.0x
Altman Z-score 3.78 – 45.44

Shareholder Returns

7 metrics
MetricALNYARGXROIV
Dividend yield – – –
Net buyback yield -0.5% – 0.4%
Shareholder yield -0.5% – 0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALNYARGXROIV
Forward P/E 8.6xFY2026 32.8xFY2026 –
EPS, next fiscal year $19.15FY2026 $29.27FY2026 $-1.22FY2026
EPS growth, next FY +721.9%FY2026 +49.6%FY2026 –
EPS growth, the year after -56.0% +32.0% –
Revenue, next fiscal year $5.65BFY2026 $6.16BFY2026 $158.10MFY2026
Revenue growth, next FY +52.2%FY2026 +44.9%FY2026 +1,814.0%FY2026
Revenue growth, the year after +23.3% +24.0% +317.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALNYARGXROIV
Held by institutions 99.7% 46.1% 77.0%
Institutions holding 788 506 500
Change in shares held, QoQ +3.8% -2.0% +5.1%
Institutions buying 412 263 304
Institutions selling 279 162 138
Buyers to sellers 1.48 1.62 2.20

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALNYARGXROIV
ALNY 1.00 0.15 0.02
ARGX 0.15 1.00 0.24
ROIV 0.02 0.24 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALNY, ARGX and ROIV?

Argenx Se (ARGX) is the largest by market capitalisation: Alnylam Pharmaceuticals (ALNY) $21.33B, Argenx Se (ARGX) $58.18B, Roivant Sciences (ROIV) $27.84B.

Which stock is cheaper, ALNY, ARGX and ROIV?

Alnylam Pharmaceuticals (ALNY) trades on the lowest price-to-earnings ratio (Alnylam Pharmaceuticals (ALNY) 8.1x, Argenx Se (ARGX) 31.0x, Roivant Sciences (ROIV) -80.8x). On next year's consensus earnings, Alnylam Pharmaceuticals (ALNY) is cheapest (Alnylam Pharmaceuticals (ALNY) 8.6x, Argenx Se (ARGX) 32.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Roivant Sciences (ROIV) grew revenue fastest over the trailing twelve months: Alnylam Pharmaceuticals (ALNY) +60.8%, Argenx Se (ARGX) +61.5%, Roivant Sciences (ROIV) +102.1%.

Which company is more profitable?

Alnylam Pharmaceuticals (ALNY) has the highest net margin (Alnylam Pharmaceuticals (ALNY) 52.8%, Argenx Se (ARGX) 32.3%, Roivant Sciences (ROIV) -838.2%).

Which stock has performed better?

Over the past year Roivant Sciences (ROIV) returned the most: Alnylam Pharmaceuticals (ALNY) -63.6%, Argenx Se (ARGX) +7.7%, Roivant Sciences (ROIV) +92.3%. Over five years, Roivant Sciences (ROIV) compounded fastest (Alnylam Pharmaceuticals (ALNY) -0.7%/yr, Argenx Se (ARGX) +25.4%/yr, Roivant Sciences (ROIV) +36.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Argenx Se (ARGX) has been the steadiest (Alnylam Pharmaceuticals (ALNY) 59.1%, Argenx Se (ARGX) 37.7%, Roivant Sciences (ROIV) 46.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALNY, ARGX and ROIV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.